Gaudium IVF & Women Health IPO: GMP, Price, Important dates and more...
- Gabriela Galeena
- 1 day ago
- 2 min read
The company has set a price band of ₹75 to ₹79 per equity share, with a lot size of 189 shares, translating to a minimum investment of ₹14,931 for retail investors.
IPO Snapshots
Detail | Value |
Total Issue Size | ₹165 Cr |
Fresh Issue | ₹90 Cr |
Offer for Sale | ₹75 Cr |
Face Value | ₹5 |
Price Band | ₹75 to ₹79 |
Lot Size | 189 |
Minimum Investment | ₹14,931 |
Listing | BSE, NSE |
Opens | 20 February 2026 |
Closes | 24 February 2026 |
Gaudium IVF and Women Health Limited is a specialised fertility and reproductive healthcare provider headquartered in New Delhi. Founded in 2009 by renowned infertility specialist Dr Manika Khanna and formally incorporated in 2015, the company focuses on assisted reproductive technology (ART), including IVF, ICSI, IUI, fertility diagnostics, egg and embryo freezing, genetic testing (PGT), male infertility treatment, and high-risk pregnancy care.
Gaudium operates with a patient-centric approach, combining advanced laboratory infrastructure with personalised treatment plans to improve clinical outcomes for couples facing infertility challenges. With increasing awareness, delayed parenthood trends, and rising acceptance of assisted reproductive treatments in India, the company positions itself as a focused player in the expanding IVF and women’s healthcare segment.
Financial Performance
Period Ended | Revenue from Operations (₹ Cr) | Profit After Tax (₹ Cr) |
FY 2025 | 70.72 | 19.13 |
FY 2024 | 47.89 | 10.32 |
FY 2023 | 44.23 | 13.52 |
GMP (Grey Market Premium)
Currently, the Grey Market Premium (GMP) of Gaudium IVF IPO is ₹4, hinting at a potential listing price of ₹83 (cap price + latest GMP). This implies an expected gain/ loss of 5.06% per share at listing.
Peer Comparison
There are currently no directly comparable listed peers in the Indian market, with the company benchmarking itself only against international players.
Use of Proceeds
The company intends to utilise the net proceeds from the fresh issue primarily to fund capital expenditure for the establishment of new IVF centres and to repay or pre-pay certain outstanding loans. The remaining funds will be allocated towards general corporate purposes, in line with SEBI regulations.
Disclaimer: This content is for educational purposes only; please conduct your own research and consult a qualified investment advisor before making investment decisions.
Want to read more?
Subscribe to finsightsbysquareleague.com to keep reading this exclusive post.
